1 / 26

Respiratory Distress Syndrome

Respiratory Distress Syndrome. Resident Lecture Series Soo Hyun Kwon, MD Neonatal-Perinatal Fellow. Overview. Definition Epidemiology Lung Development Pathophysiology Risk Factors Clinical Manifestations DDx Diagnosis Treatment. Objectives.

alan-webb
Download Presentation

Respiratory Distress Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Respiratory Distress Syndrome Resident Lecture Series Soo Hyun Kwon, MD Neonatal-Perinatal Fellow

  2. Overview • Definition • Epidemiology • Lung Development • Pathophysiology • Risk Factors • Clinical Manifestations • DDx • Diagnosis • Treatment

  3. Objectives • Define respiratory distress syndrome (RDS). • Discuss the epidemiology, pathophysiology, and diagnosis of RDS. • List a differential diagnosis for respiratory distress in the neonate. • Describe the treatments for RDS. • Discuss ventilation strategies that can be used in the infant who has RDS. • Describe long-term complications of RDS and its treatments.

  4. Definition • Formerly known as hyaline membrane disease • Deficiency of pulmonary surfactant in an immature lung • Disease of prematurity

  5. Epidemiology • Major cause of morbidity and mortality in preterm infants • 20,000-30,000 newborn infants each year • Incidence and severity of RDS are related inversely to gestational age of newborn infant • 26-28 weeks' gestation : 50% • 30-31 weeks' gestation : <30% • Overall incidence in 501-1500 grams: 42% • 501-750 grams: 71% • 751-1000 grams: 54% • 1001-1250 grams: 36% • 1251-1500 grams: 22%

  6. Phases of Lung Development

  7. Lung Development

  8. Surfactant • Complex lipoprotein • Composed of 6 phospholipids and 4 apoproteins • 70-80% phospholipids, 8-10% protein, and 10% neutral lipids

  9. Surfactant Metabolism

  10. Assessment of Fetal Lung Maturity • Lecithin/sphingomyelin (L/S) ratio • Lamellar body counts • Phosphatidylglycerol • After 35 weeks gestation

  11. L/S Ratio

  12. Pathophysiology

  13. Etiology • Preterm delivery • Mutations in genes encoding surfactant proteins • SP-B • SP-C • ATP-binding cassette (ABC) transporter A3 (ABCA3)

  14. Lung Compliance

  15. Normal Lung

  16. Hyaline Membranes

  17. Risk Factors • Prematurity • Maternal diabetes • C-section delivery • Asphyxia

  18. Surfactant Inactivation • Meconium and blood can inactivate surfactant activity (Full-term > Preterm) • Proteinaceous edema and inflammatory products increase conversion rate of surfactant into its inactive vesicular form • Oxidant and mechanical stress associated with mechanical ventilation that uses large TV

  19. Clinical Manifestations • Tachypnea • Nasal flaring • Grunting • Intercostal, subxiphoid, and subcostal retractions • Cyanosis

  20. Differential Diagnosis • TTN • MAS • Pneumonia • Cyanotic Congenital Heart Disease • Pneumomediastinum, pneumothorax • Hypoglycemia • Metabolic problems • Hematologic problems • Anemia, polycythemia • Congenital anomalies of the lungs

  21. Diagnosis • Onset of progressive respiratory failure shortly after birth • Characteristic chest radiograph • ABG • Hypoxia • Hypercarbia

  22. CXR

  23. Prevention • Antenatal glucocorticoids • Enhances maturational changes in lung architecture and inducing enzymes • Stimulate phospholipid synthesis and release of surfactant • All pregnant mothers at risk for preterm delivery at or below 34 weeks gestation should receive ACS

  24. Treatment • Surfactant Therapy • Assisted Ventilation Techniques • Supportive Care • Thermoregulation • Fluid Management • Nutrition

  25. References • Jobe AH. Why Surfactant Works for Respiratory Distress Syndrome. NeoReviews. 2006; 7: 95-106. • Pramanik AK, et al. Respiratory distress syndrome. http://emedicine.medscape.com/article/976034-overview. • Saker F, Martin R. Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn. Uptodate. http://www.utdol.com • Warren JB, Andersen JM. Respiratory distress syndrome. Neoreviews. 2009; 7: 351-361.

  26. Questions or Comments?

More Related